WUHAN, Hubei, China, May 6 /Xinhua-PRNewswire-FirstCall/ -- Benda
Pharmaceutical, Inc. (OTC Bulletin Board: BPMA), a China-based
pharmaceutical company producing both Gendicine(R), a commercialized gene
therapy medicine for the treatment of cancer, and traditional Chinese and
conventional medicines, today filed an amendment to the Company's Form S-1
application with the Securities and Exchange Commission ("SEC"). The
amendment covers the resale by selling stockholders of up to 17,880,936
shares of common stock, $.001 par value, which includes:
1. 2,106,561 shares of common stock; and
2. 15,774,375 shares of common stock based on 150% of the common stock
issuable upon exercise of outstanding warrants issued at an exercise
price of $0.555 per share in conjunction with the private placements
completed on November 15, 2006 and April 5, 2007.
Mr. Charles Wan, Chief Executive Officer of Benda Pharmaceutical, stated, "We are pleased to file the amendment which takes us one step further to completing our S-1 registration."
Additional information regarding this registration can be found in the Company's Registration Statement on Form S-1/A, as filed with the SEC on May 5, 2008, which can be viewed at http://www.sec.gov .
About Benda Pharmaceutical, Inc.
Benda Pharmaceutical, Inc. ( http://www.bendapharma.com ), a China-based pharmaceutical company, produces traditional Chinese and conventional medicines, as well as Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer.
Safe Harbor Statement
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.
|SOURCE Benda Pharmaceutical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved